PET/CT scans using MET or FET tracers in glioma and parathyroid disease
Tests PET/CT imaging to find tumor lesions in adults with amino acid transporter diseases.
Key facts
- Who runs it
- Tianjin Medical University
- Where
- China3 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 29 Aug 2013
- Expected to end
- 29 Aug 2033
- Type of study
- Observational
- Treatments tested
- 11C/18F-MET/FET
- Record updated
- 8 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a suspected, new or previously treated cancer who have a planned amino acid PET/CT scan (11C/18F-MET/FET).
- Age
- 18 Years to 90 Years
- Sex
- All sexes
- Disease stage
- Suspected, newly diagnosed or previously treated malignant tumors, primary or spread (metastatic) lesions.
- Earlier treatment
- People with no prior treatment and people already treated can both join.
Main reasons for not taking part
- Lesions that are not cancer
- Pregnancy
- Unable or unwilling to give written informed consent
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- adult patients (aged 18 years or order)
- patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report)
- patients who had scheduled AATS PET/CT scan
- patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee
Who cannot take part
- patients with non-malignant lesions
- patients with pregnancy
- the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the potential usefulness of 11C/18F-MET/FET positron emission tomography/ computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various amino acid transporter system (AATS)-related disease patients.
The group in the trial
- Single Group Assignment
Each subject receive a single intravenous injection of 11C/18F-MET/FET, and undergo PET/CT imaging within the specificed time.
Treatment: 11C/18F-MET/FET
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases
- Plain-language title
- PET/CT scans using MET or FET tracers in glioma and parathyroid diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07379463, who can take part
- Record updated
- 8 September 2026